KASEY KEENE: Open Payments
NPI 1013332246 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,335 in 73 payments from 17 companies in 2025. Trend: 2023 $739 · 2024 $915 · 2025 $1,335
Food & beverage: $1,335
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $340 |
| Sumitomo Pharma America, Inc. | 21 | $192 |
| Dendreon Pharmaceuticals LLC | 5 | $158 |
| Astellas Pharma US Inc | 9 | $139 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $110 |
| IMMUNITYBIO, INC. | 2 | $65 |
| ABBVIE INC. | 2 | $49 |
| Olympus America Inc. | 2 | $41 |
| ACCORD HEALTHCARE, INC. | 2 | $39 |
| Merck Sharp & Dohme LLC | 1 | $34 |
Products named: ERLEADA, PROVENGE, Xtandi, GEMTESA, Nubeqa, ORGOVYX, ANKTIVA, BOTOX.
Industry payments across TX — which companies pay providers there.
